Chainlink has formed a strategic partnership with South Korea's LG CNS to develop digital asset services aimed at Korean institutions, targeting a market valued at $68 billion. LG CNS will integrate Chainlink's cross-chain, data, and orchestration infrastructure into its digital asset platform and plans to create institutional solutions using Chainlink’s technology. LG CNS, part of the LG Group and a key contractor for the Bank of Korea’s digital currency project, has prior experience exploring tokenized-asset services with Securitize. This partnership could significantly enhance digital asset offerings for Korean financial institutions.
Chainlink and LG CNS digital asset partnership is the subject, providing context for readers. For those tracking major cryptocurrencies on Pluang, 44 of 50 rose and 5 fell today. ONE (Harmony) rose 2.59% to Rp26 with 97% buy orders; GRT (The Graph) rose 2.49% to Rp433 with 72% buy orders; ADA (Cardano) rose 2.31% to Rp3,893 with 75% buy orders. Data as of Oct 24, 2026 00:22 WIB.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
